|
|
|
|
DepocytdBusinessNews Newark (press release), ...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in North America. In ... Enzon Returns Rights to Transplantation Product to Fresenius ... Jan 6, 2006 Finanzen.net, ...totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R),ADAGEN(R), and DEPOCYT(R) in ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |